RRM2 and glioblastoma: At present, the clinical management of glioblastoma, chronic granulocytic leukemia, acute granulocytic leukemia, and sickle cell anemia has incorporated the utilization of inhibitors that specifically target RRM2, yielding favorable therapeutic outcomes [11–13].